The Tumor Macroenvironment: Cancer-Promoting Networks Beyond Tumor Beds

Advances in Cancer Research

Volumn 128, Issue , 2015, Pages 235-262

  Rutkowski, Melanie R ^a   Svoronos, Nikolaos ^a   Perales Puchalt, Alfredo ^a   Conejo Garcia, Jose R ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

Commensal microbiota; Emergency myelopoiesis; Hormones; MDSC; Microbiota; Premetastatic niche; Tumor microenvironment; Tumor promoting inflammation

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANDROGEN RECEPTOR; ANDROSTANOLONE; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; ESTRADIOL; ESTRIOL; ESTROGEN RECEPTOR; ESTRONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INSULIN; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; PATTERN RECOGNITION RECEPTOR; PROSTAGLANDIN E2; SOMATOMEDIN C; STAT3 PROTEIN; TESTOSTERONE; TOLL LIKE RECEPTOR 5;

ARTICLE; BREAST CANCER; CANCER STEM CELL; CELL LINEAGE; CELL POPULATION; COMMENSAL; CYTOKINE RELEASE; DISEASE COURSE; GENE OVEREXPRESSION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; METASTASIS; MICROFLORA; MYELOID DERIVED SUPPRESSOR CELL; MYELOID PROGENITOR CELL; MYELOPOIESIS; ONCOGENESIS AND MALIGNANT TRANSFORMATION; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; STEM CELL NICHE; SUPPRESSOR CELL; TUMOR GROWTH; TUMOR INVASION; TUMOR MACROENVIRONMENT; TUMOR SEEDING; CELL EXPANSION; CELL SUBPOPULATION; HORMONE SYNTHESIS; IMMUNOCOMPETENT CELL; MALIGNANT TRANSFORMATION; NONHUMAN; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; ANIMAL; IMMUNOLOGY; NEOPLASM; PATHOLOGY;

ANIMALS; DISEASE PROGRESSION; HUMANS; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84952863470     PISSN: 0065230X     EISSN: 21625557     Source Type: Book Series    
DOI: 10.1016/bs.acr.2015.04.011     Document Type: Chapter

References (133)

1. Abt M.C., Osborne L.C., Monticelli L.A., Doering T.A., Alenghat T., Sonnenberg G.F., et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity 2012, 37:158-170.
2. Anderson G.L., Judd H.L., Kaunitz A.M., Barad D.H., Beresford S.A., Pettinger M., et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: The Women's Health Initiative randomized trial. JAMA 2003, 290:1739-1748.
3. Argenta P.A., Thomas S.G., Judson P.L., Downs L.S., Geller M.A., Carson L.F., et al. A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer. Gynecologic Oncology 2009, 113:205-209.
4. Arpaia N., Campbell C., Fan X., Dikiy S., van der Veeken J., Deroos P., et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013, 504(7480):451-455.
5. Arthur, J. C., Perez-Chanona, E., Mühlbauer, M., Tomkovich, S., Uronis, J. M., Fan, T.-J. J., et al. (2012). Intestinal inflammation targets cancer-inducing activity of the microbiota. Science (New York, NY), 338, 120-123.
6. Baird J.R., Byrne K.T., Lizotte P.H., Toraya-Brown S., Scarlett U.K., Alexander M.P., et al. Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge. Journal of Immunology 2013, 190:469-478.
7. Baird J.R., Fox B.A., Sanders K.L., Lizotte P.H., Cubillos-Ruiz J.R., Scarlett U.K., et al. Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment. Cancer Research 2013, 73:3842-3851.
8. Barretina J., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607.
9. Beatty G.L., Chiorean E.G., Fishman M.P., Saboury B., Teitelbaum U.R., Sun W., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616.
10. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362:419-427.
11. Beral V., Bull D., Green J., Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007, 369:1703-1710.
12. Bossard C., Busson M., Vindrieux D., Gaudin F., Machelon V., Brigitte M., et al. Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancer. PLoS One 2012, 7:e44787.
13. Bunt S.K., Yang L., Sinha P., Clements V.K., Leips J., Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Research 2007, 67:10019-10026.
14. Burstein H.J., Temin S., Anderson H., Buchholz T.A., Davidson N.E., Gelmon K.E., et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update. Journal of Clinical Oncology 2014, 32:2255-2269.
15. Casanova J.L., Abel L., Quintana-Murci L. Human TLRs and IL-1Rs in host defense: Natural insights from evolutionary, epidemiological, and clinical genetics. Annual Review of Immunology 2011, 29:447-491.
16. Chalmin F., Ladoire S., Mignot G., Vincent J., Bruchard M., Remy-Martin J.P., et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. The Journal of Clinical Investigation 2010, 120:457-471.
17. Chan J.M., Stampfer M.J., Giovannucci E., Gann P.H., Ma J., Wilkinson P., et al. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998, 279:563-566.
18. Chappert P., Bouladoux N., Naik S., Schwartz R.H. Specific gut commensal flora locally alters T cell tuning to endogenous ligands. Immunity 2013, 38:1198-1210.
19. Chen W.C., Lai Y.H., Chen H.Y., Guo H.R., Su I.J., Chen H.H. Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor. Histopathology 2013, 63:225-233.
20. Chen Q., Zhang X.H., Massague J. Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell 2011, 20:538-549.
21. Cheng P., Corzo C.A., Luetteke N., Yu B., Nagaraj S., Bui M.M., et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. The Journal of Experimental Medicine 2008, 205:2235-2249.
22. Chiba S., Baghdadi M., Akiba H., Yoshiyama H., Kinoshita I., Dosaka-Akita H., et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nature Immunology 2012, 13:832-842.
23. Clarke T.B., Davis K.M., Lysenko E.S., Zhou A.Y., Yu Y., Weiser J.N. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nature Medicine 2010, 16:228-231.
24. Condamine T., Kumar V., Ramachandran I.R., Youn J.I., Celis E., Finnberg N., et al. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. The Journal of Clinical Investigation 2014, 124:2626-2639.
25. Conejo-Garcia J.R., Benencia F., Courreges M.C., Kang E., Mohamed-Hadley A., Buckanovich R.J., et al. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of VEGF-A. Nature Medicine 2004, 10:950-958.
26. Corzo C.A., Condamine T., Lu L., Cotter M.J., Youn J.I., Cheng P., et al. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. The Journal of Experimental Medicine 2010, 207:2439-2453.
27. Corzo C.A., Cotter M.J., Cheng P., Cheng F., Kusmartsev S., Sotomayor E., et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. Journal of Immunology 2009, 182:5693-5701.
28. Cubillos-Ruiz J.R., Baird J.R., Tesone A.J., Rutkowski M.R., Scarlett U.K., Camposeco-Jacobs A.L., et al. Reprogramming tumor-associated dendritic cells in vivo using microRNA mimetics triggers protective immunity against ovarian cancer. Cancer Research 2012, 72:1683-1693.
29. Cubillos-Ruiz J.R., Martinez D., Scarlett U.K., Rutkowski M.R., Nesbeth Y.C., Camposeco-Jacobs A.L., et al. CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells. Oncotarget 2010, 1:329-338.
30. Diel P. Tissue-specific estrogenic response and molecular mechanisms. Toxicology Letters 2002, 127:217-224.
31. Dolcetti L., Peranzoni E., Ugel S., Marigo I., Fernandez Gomez A., Mesa C., et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. European Journal of Immunology 2010, 40:22-35.
32. Duan J., Chung H., Troy E., Kasper D.L. Microbial colonization drives expansion of IL-1 receptor 1-expressing and IL-17-producing gamma/delta T cells. Cell Host & Microbe 2010, 7:140-150.
33. Dunn S.E., Kari F.W., French J., Leininger J.R., Travlos G., Wilson R., et al. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Research 1997, 57:4667-4672.
34. Eruslanov E.B., Bhojnagarwala P.S., Quatromoni J.G., Stephen T.L., Ranganathan A., Deshpande C., et al. Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. The Journal of Clinical Investigation 2014, 124:5466-5480.
35. Eruslanov E., Daurkin I., Ortiz J., Vieweg J., Kusmartsev S. Pivotal advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE(2) catabolism in myeloid cells. Journal of Leukocyte Biology 2010, 88:839-848.
36. Farhat G.N., Cummings S.R., Chlebowski R.T., Parimi N., Cauley J.A., Rohan T.E., et al. Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. Journal of the National Cancer Institute 2011, 103:562-570.
37. Farren M.R., Carlson L.M., Netherby C.S., Lindner I., Li P.K., Gabrilovich D.I., et al. Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKCbetaII abundance. Science Signaling 2014, 7:ra16.
38. Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nature Reviews. Cancer 2001, 1:34-45.
39. Fierz Y., Novosyadlyy R., Vijayakumar A., Yakar S., LeRoith D. Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Diabetes 2010, 59:686-693.
40. Fukuda A., Wang S.C., Morris J.P.T., Folias A.E., Liou A., Kim G.E., et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 2011, 19:441-455.
41. Furusawa Y., Obata Y., Fukuda S., Endo T.A., Nakato G., Takahashi D., et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013, 504(7480):446-450.
42. Gabrilovich D.I., Bronte V., Chen S.H., Colombo M.P., Ochoa A., Ostrand-Rosenberg S., et al. The terminology issue for myeloid-derived suppressor cells. Cancer Research 2007, 67:425. author reply 426.
43. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nature Reviews. Immunology 2012, 12:253-268.
44. Galien R., Garcia T. Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site. Nucleic Acids Research 1997, 25:2424-2429.
45. Garnett M.J., Edelman E.J., Heidorn S.J., Greenman C.D., Dastur A., Lau K.W., et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483:570-575.
46. George A.L., Rajoria S., Suriano R., Mittleman A., Tiwari R.K. Hypoxia and estrogen are functionally equivalent in breast cancer-endothelial cell interdependence. Molecular Cancer 2012, 11:80.
47. Ghajar C.M., Peinado H.C., Mori H., Matei I.R., Evason K.J., Brazier H., et al. The perivascular niche regulates breast tumour dormancy. Nature Cell Biology 2013, 15:807-817.
48. Gil M., Komorowski M.P., Seshadri M., Rokita H., McGray A.J., Opyrchal M., et al. CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells. Journal of Immunology 2014, 193:5327-5337.
49. Gil M., Seshadri M., Komorowski M.P., Abrams S.I., Kozbor D. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proceedings of the National Academy of Sciences of the United States of America 2013, 110:E1291-E1300.
50. Green S.M., Mostaghel E.A., Nelson P.S. Androgen action and metabolism in prostate cancer. Molecular and Cellular Endocrinology 2012, 360:3-13.
51. Groothuis P.G., Dassen H.H., Romano A., Punyadeera C. Estrogen and the endometrium: Lessons learned from gene expression profiling in rodents and human. Human Reproduction Update 2007, 13:405-417.
52. Gros A., Turcotte S., Wunderlich J.R., Ahmadzadeh M., Dudley M.E., Rosenberg S.A. Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clinical Cancer Research 2012, 18:5212-5223.
53. Haibe-Kains B., El-Hachem N., Birkbak N.J., Jin A.C., Beck A.H., Aerts H.J., et al. Inconsistency in large pharmacogenomic studies. Nature 2013, 504:389-393.
54. Hamelers I.H., Van Schaik R.F., Sussenbach J.S., Steenbergh P.H. 17beta-Estradiol responsiveness of MCF-7 laboratory strains is dependent on an autocrine signal activating the IGF type I receptor. Cancer Cell International 2003, 3:10.
55. Hankinson S.E., Willett W.C., Colditz G.A., Hunter D.J., Michaud D.S., Deroo B., et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998, 351:1393-1396.
56. Hartman Z.C., Poage G.M., den Hollander P., Tsimelzon A., Hill J., Panupinthu N., et al. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Research 2013, 73:3470-3480.
57. Hawn T.R., Verbon A., Lettinga K.D., Zhao L.P., Li S.S., Laws R.J., et al. A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to Legionnaires' disease. The Journal of Experimental Medicine 2003, 198:1563-1572.
58. Hemkens L.G., Grouven U., Bender R., Gunster C., Gutschmidt S., Selke G.W., et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: A cohort study. Diabetologia 2009, 52:1732-1744.
59. Herger C.C., Sauer H.R. A consideration of the effect of androgen control treatment of carcinoma of the prostate. New York State Journal of Medicine 1947, 47:494-501.
60. Holten-Andersen M.N., Stephens R.W., Nielsen H.J., Murphy G., Christensen I.J., Stetler-Stevenson W., et al. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clinical Cancer Research 2000, 6:4292-4299.
61. Hu B., Elinav E., Huber S., Strowig T., Hao L., Hafemann A., et al. Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer. Proceedings of the National Academy of Sciences of the United States of America 2013, 110:9862-9867.
62. Huarte E., Cubillos-Ruiz J.R., Nesbeth Y.C., Scarlett U.K., Martinez D.G., Buckanovich R.J., et al. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Research 2008, 68:7684-7691.
63. Ichinohe T., Pang I.K., Kumamoto Y., Peaper D.R., Ho J.H., Murray T.S., et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:5354-5359.
64. Ignatov T., Modl S., Thulig M., Weissenborn C., Treeck O., Ortmann O., et al. GPER-1 acts as a tumor suppressor in ovarian cancer. Journal of Ovarian Research 2013, 6:51.
65. Iida N., Dzutsev A., Stewart C.A., Smith L., Bouladoux N., Weingarten R.A., et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science (New York, NY) 2013, 342:967-970.
66. Ivanov I.I., Frutos R.de L., Manel N., Yoshinaga K., Rifkin D.B., Sartor R.B., et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host & Microbe 2008, 4:337-349.
67. Iyer V., Klebba I., McCready J., Arendt L.M., Betancur-Boissel M., Wu M.F., et al. Estrogen promotes ER-negative tumor growth and angiogenesis through mobilization of bone marrow-derived monocytes. Cancer Research 2012, 72:2705-2713.
68. Jakacka M., Ito M., Weiss J., Chien P.Y., Gehm B.D., Jameson J.L. Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. The Journal of Biological Chemistry 2001, 276:13615-13621.
69. Jin D.K., Shido K., Kopp H.G., Petit I., Shmelkov S.V., Young L.M., et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nature Medicine 2006, 12:557-567.
70. Kaplan R.N., Rafii S., Lyden D. Preparing the "soil": The premetastatic niche. Cancer Research 2006, 66:11089-11093.
71. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438:820-827.
72. Keskinov A.A., Shurin M.R. Myeloid regulatory cells in tumor spreading and metastasis. Immunobiology 2015, 220:236-242.
73. Kissick H.T., Sanda M.G., Dunn L.K., Pellegrini K.L., On S.T., Noel J.K., et al. Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. Proceedings of the National Academy of Sciences of the United States of America 2014, 111:9887-9892.
74. Kroemer G., Galluzzi L., Kepp O., Zitvogel L. Immunogenic cell death in cancer therapy. Annual Review of Immunology 2012, 31:51-72.
75. Kryczek I., Banerjee M., Cheng P., Vatan L., Szeliga W., Wei S., et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009, 114:1141-1149.
76. Kusmartsev S., Gabrilovich D.I. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunology, Immunotherapy 2002, 51:293-298.
77. Lechner M.G., Liebertz D.J., Epstein A.L. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. Journal of Immunology 2010, 185:2273-2284.
78. Lesina M., Kurkowski M.U., Ludes K., Rose-John S., Treiber M., Kloppel G., et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011, 19:456-469.
79. Lindemann K., Malander S., Christensen R.D., Mirza M.R., Kristensen G.B., Aavall-Lundqvist E., et al. Examestane in advanced or recurrent endometrial carcinoma: A prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO). BMC Cancer 2014, 14:68.
80. Loblaw D.A., Mendelson D.S., Talcott J.A., Virgo K.S., Somerfield M.R., Ben-Josef E., et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. Journal of Clinical Oncology 2004, 22:2927-2941.
81. Lu X., Mu E., Wei Y., Riethdorf S., Yang Q., Yuan M., et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell 2011, 20:701-714.
82. Ma J., Pollak M.N., Giovannucci E., Chan J.M., Tao Y., Hennekens C.H., et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. Journal of the National Cancer Institute 1999, 91:620-625.
83. Marigo I., Bosio E., Solito S., Mesa C., Fernandez A., Dolcetti L., et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2010, 32:790-802.
84. Melmed S. Acromegaly pathogenesis and treatment. The Journal of Clinical Investigation 2009, 119:3189-3202.
85. Meredith M.M., Liu K., Darrasse-Jeze G., Kamphorst A.O., Schreiber H.A., Guermonprez P., et al. Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage. The Journal of Experimental Medicine 2012, 209:1153-1165.
86. Minn A.J., Gupta G.P., Padua D., Bos P. Lung metastasis genes couple breast tumor size and metastatic spread. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:6740-6745.
87. Müller A., Homey B., Soto H., Ge N., Catron D. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410(6824):50-56.
88. Nagaraj S., Gabrilovich D.I. Regulation of suppressive function of myeloid-derived suppressor cells by CD4+ T cells. Seminars in Cancer Biology 2012, 22:282-288.
89. Narita Y., Wakita D., Ohkur T., Chamoto K., Nishimura T. Potential differentiation of tumor bearing mouse CD11b+Gr-1+ immature myeloid cells into both suppressor macrophages and immunostimulatory dendritic cells. Biomedical Research 2009, 30:7-15.
90. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317:121-124.
91. Nefedova Y., Huang M., Kusmartsev S., Bhattacharya R., Cheng P., Salup R., et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. Journal of Immunology 2004, 172:464-474.
92. Nilsson S., Makela S., Treuter E., Tujague M., Thomsen J., Andersson G., et al. Mechanisms of estrogen action. Physiological Reviews 2001, 81:1535-1565.
93. Novosyadlyy R., Lann D.E., Vijayakumar A., Rowzee A., Lazzarino D.A., Fierz Y., et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Research 2010, 70:741-751.
94. Noy R., Pollard J.W. Tumor-associated macrophages: From mechanisms to therapy. Immunity 2014, 41:49-61.
95. Nunez N.P., Jelovac D., Macedo L., Berrigan D., Perkins S.N., Hursting S.D., et al. Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer. Clinical Cancer Research 2004, 10:5375-5380.
96. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: Linking inflammation and cancer. Journal of Immunology 2009, 182:4499-4506.
97. Peinado H., Aleckovic M., Lavotshkin S., Matei I., Costa-Silva B., Moreno-Bueno G., et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature Medicine 2012, 18:883-891.
98. Psaila B., Lyden D. The metastatic niche: Adapting the foreign soil. Nature Reviews. Cancer 2009, 9:285-293.
99. Ramachandran I.R., Martner A., Pisklakova A., Condamine T., Chase T., Vogl T., et al. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. Journal of Immunology 2013, 190:3815-3823.
100. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
101. Rutkowski M.R., Stephen T.L., Conejo-Garcia J.R. Anti-tumor immunity: Myeloid leukocytes control the immune landscape. Cellular Immunology 2012, 278:21-26.
102. Rutkowski M.R., Stephen T.L., Svoronos N., Allegrezza M.J., Tesone A.J., Perales-Puchalt A., et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell 2015, 27:27-40.
103. Ryzhov S., Novitskiy S.V., Goldstein A.E., Biktasova A., Blackburn M.R., Biaggioni I., et al. Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells. Journal of Immunology 2011, 187:6120-6129.
104. Sander L.E., Sackett S.D., Dierssen U., Beraza N., Linke R.P., Muller M., et al. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. The Journal of Experimental Medicine 2010, 207:1453-1464.
105. Scarlett U.K., Cubillos-Ruiz J.R., Nesbeth Y.C., Martinez D.G., Engle X., Gewirtz A.T., et al. In situ stimulation of CD40 and toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Research 2009, 69:7329-7337.
106. Scarlett U.K., Rutkowski M.R., Rauwerdink A.M., Fields J., Escovar-Fadul X., Baird J., et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. The Journal of Experimental Medicine 2012, 209:495-506.
107. Sceneay J., Smyth M.J., Moller A. The pre-metastatic niche: Finding common ground. Cancer Metastasis Reviews 2013, 32:449-464.
108. Schraml B.U., van Blijswijk J., Zelenay S., Whitney P.G., Filby A., Acton S.E., et al. Genetic tracing via DNGR-1 expression history defines dendritic cells as a hematopoietic lineage. Cell 2013, 154:843-858.
109. Seubert B., Grunwald B., Kobuch J., Cui H., Schelter F., Schaten S., et al. Tissue inhibitor of metalloproteinases (TIMP)-1 creates a premetastatic niche in the liver through SDF-1/CXCR4-dependent neutrophil recruitment in mice. Hepatology 2015, 61:238-248.
110. Sharifi N. Mechanisms of androgen receptor activation in castration-resistant prostate cancer. Endocrinology 2013, 154:4010-4017.
111. Sieveking D.P., Lim P., Chow R.W., Dunn L.L., Bao S., McGrath K.C., et al. A sex-specific role for androgens in angiogenesis. The Journal of Experimental Medicine 2010, 207:345-352.
112. Sinha P., Clements V.K., Fulton A.M., Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Research 2007, 67:4507-4513.
113. Sinha P., Okoro C., Foell D., Freeze H.H., Ostrand-Rosenberg S., Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. Journal of Immunology 2008, 181:4666-4675.
114. Swaby R.F., Sharma C.G., Jordan V.C. SERMs for the treatment and prevention of breast cancer. Reviews in Endocrine & Metabolic Disorders 2007, 8:229-239.
115. Takizawa H., Boettcher S., Manz M.G. Demand-adapted regulation of early hematopoiesis in infection and inflammation. Blood 2012, 119:2991-3002.
116. Thompson C.L., Vier R., Mikaelyan A., Wienemann T., Brune A. 'Candidatus Arthromitus' revised: Segmented filamentous bacteria in arthropod guts are members of Lachnospiraceae. Environmental Microbiology 2012, 14:1454-1465.
117. Tseng D., Vasquez-Medrano D.A., Brown J.M. Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas. British Journal of Cancer 2011, 104:1805-1809.
118. Viaud S., Saccheri F., Mignot G., Yamazaki T., Daillère R., Hannani D., et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (New York, NY) 2013, 342:971-976.
119. Vicari A.P., Chiodoni C., Vaure C., Ait-Yahia S., Dercamp C., Matsos F., et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. The Journal of Experimental Medicine 2002, 196:541-549.
120. Wei S., Kryczek I., Zou L., Daniel B., Cheng P., Mottram P., et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Research 2005, 65:5020-5026.
121. Wei B., Wingender G., Fujiwara D., Chen D.Y., McPherson M., Brewer S., et al. Commensal microbiota and CD8+ T cells shape the formation of invariant NKT cells. Journal of Immunology (Baltimore, Md.: 1950) 2010, 184:1218-1226.
122. Weiderpass E., Adami H.O., Baron J.A., Magnusson C., Bergstrom R., Lindgren A., et al. Risk of endometrial cancer following estrogen replacement with and without progestins. Journal of the National Cancer Institute 1999, 91:1131-1137.
123. Wong D., Kandagatla P., Korz W., Chinni S.R. Targeting CXCR4 with CTCE-9908 inhibits prostate tumor metastasis. BMC Urology 2014, 14:12.
124. Wu Y., Cui K., Miyoshi K., Hennighausen L., Green J.E., Setser J., et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Research 2003, 63:4384-4388.
125. Wu Y., Yakar S., Zhao L., Hennighausen L., LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Research 2002, 62:1030-1035.
126. Yan L., Cai Q., Xu Y. The ubiquitin-CXCR4 axis plays an important role in acute lung infection-enhanced lung tumor metastasis. Clinical Cancer Research 2013, 19:4706-4716.
127. Yang L., DeBusk L.M., Fukuda K., Fingleton B., Green-Jarvis B., Shyr Y., et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004, 6:409-421.
128. Youn J.I., Collazo M., Shalova I.N., Biswas S.K., Gabrilovich D.I. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. Journal of Leukocyte Biology 2012, 91:167-181.
129. Youn J.I., Kumar V., Collazo M., Nefedova Y., Condamine T., Cheng P., et al. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nature Immunology 2013, 14:211-220.
130. Youn J.I., Nagaraj S., Collazo M., Gabrilovich D.I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. Journal of Immunology 2008, 181:5791-5802.
131. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nature Reviews. Cancer 2009, 9:798-809.
132. Zhang H., Fagan D.H., Zeng X., Freeman K.T., Sachdev D., Yee D. Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene 2010, 29:2517-2527.
133. Zhang L.J., Xiong Y., Nilubol N., He M., Bommareddi S., Zhu X., et al. Testosterone regulates thyroid cancer progression by modifying tumor suppressor-genes and tumor immunity. Carcinogenesis 2015, 36(4):420-428.